United Kingdom (UK)
Recombinant monoclonal antibody to CD44v6. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma BIWA4.
UniProt Accession Number of Target Protein: P16070
Alternative Name(s) of Target: bivatuzumab; CD44 antigen; CDw44; Epican; Extracellular matrix receptor III; ECMR-III; GP90 lymphocyte homing/adhesion receptor; HUTCH-I; Heparan sulfate proteoglycan; Hermes antigen; Hyaluronate receptor; Phagocytic glycoprotein 1; PGP-1; Phagocytic glycoprotein I; PGP-I
Immunogen: The antibody is the humanized version of the murine BIWA-1.
Specificity: The antibody is specific for CD44v6. The antibody recognises an epitope encoded by variant exon v6 of CD44. CD44v6 is a tumor associated antigen abundantly expressed in head and neck squamous cell carcinomas (HNSCC) and in normal squamous epithelium.
Application Notes: The binding affinity of the antibody to CD44v6 was measured by surface plasmon resonance. The antibody showed a specificity of tumor localization when administrated together with another anti-CD44v6 antibody in mice in in vivo experiments (Verel et al. 2002; PMID: 11992408). The specificity of the humanized version of the antibody was confirmed by ELISA anlaysis (Kd= 3.4 nM). The antibody had good therapeutic efficacy, biodistribution and tumor uptake in in vivo experiments in mice. Mice treated with 186Re-BIWA 4 showed a decreased in the tumor volume (US6972324B2). The radioactively labelled humanized version of the antibody was employed in a clinical trial in patients with advanced squamous cell carcinoma of the head and neck showing promising antitumor effects (Börjesson et al., 2003; PMID: 14506195).
Antibody first published in: PMID: